HomeN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Previous close
R$34.41
Year range
R$25.64 - R$44.95
Market cap
11.45B USD
Avg Volume
19.00
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 572.60M | 11.12% |
Operating expense | 276.50M | 13.74% |
Net income | 7.90M | -81.80% |
Net profit margin | 1.38 | -83.61% |
Earnings per share | 0.70 | -41.67% |
EBITDA | 31.30M | -71.93% |
Effective tax rate | 46.26% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 943.50M | -22.06% |
Total assets | 3.69B | 6.20% |
Total liabilities | 1.15B | 6.05% |
Total equity | 2.54B | — |
Shares outstanding | 98.97M | — |
Price to book | 1.34 | — |
Return on assets | 1.60% | — |
Return on capital | 1.94% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | 7.90M | -81.80% |
Cash from operations | 64.80M | -50.27% |
Cash from investing | 14.20M | 125.82% |
Cash from financing | -117.90M | -268.67% |
Net change in cash | -38.90M | -126.79% |
Free cash flow | 28.91M | -88.50% |
About
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Founded
1992
Headquarters
Website
Employees
1,800
